-
公开(公告)号：US20230355874A1
公开(公告)日：2023-11-09
申请号：US18353523
申请日：2023-07-17
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , Bonnie DUMAIS , Jason O'CONNOR , Yibin ZHENG
CPC classification number: A61M5/1723 , A61M5/14244 , A61M2230/201
Abstract: Disclosed are techniques and devices that are operable to receive one or a number of generalized parameters of an automated insulin delivery algorithm. An input of at least one generalized parameter corresponding to a user may be used to set one or more of the number of specific parameters of the automated insulin delivery algorithm based on the inputted at least one generalized parameter. Physiological condition data related to the user may be collected. The automated insulin delivery algorithm may determine a dosage of insulin to be delivered based on the collected physiological condition. Signals may be output to cause a liquid drug to be delivered to the user based on an output of the automated insulin delivery algorithm related to the determined dosage of insulin.
-
公开(公告)号：US20230310741A1
公开(公告)日：2023-10-05
申请号：US18192380
申请日：2023-03-29
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , Yibin ZHENG , Jason O'CONNOR , Ashutosh ZADE , James CAUSEY
IPC: A61M5/172
CPC classification number: A61M5/172 , A61M2205/50
Abstract: Disclosed herein is a drug delivery system wherein wearable components of the system are provided with Wi-Fi and/or cellular capabilities such as to allow different modalities for inter-component communications and, further, to allow access to a plethora of cloud-based services to enhance the functionality of the system.
-
23.发明公开公开(公告)号：US20230248909A1
公开(公告)日：2023-08-10
申请号：US18164669
申请日：2023-02-06
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , James GRAHAM , Jason O'CONNOR , Yibin ZHENG
CPC classification number: A61M5/1723 , G16H20/17 , A61M2202/0486 , A61M2205/52
Abstract: Disclosed are processes and techniques for a correction factor determination process for determining a correction factor for delivering a drug to a patient via a drug delivery device. For example, for an insulin delivery device, the disclosed techniques enable adjustment of the patient’s correction factor in real time based on the deviation of the patient’s glucose concentrations against clinically recommended targets. For example, a method for determining a correction factor may include determining an insulin action (Iaction) for a patient over a duration, the insulin action representing a total insulin metabolized, determining glucose information for the patient over the duration, the glucose information representing glucose activity, and determining an estimated correction factor (CFest) based on (glucose information) / (insulin action) for the duration. Other embodiments are described.
-
公开(公告)号：US20230233762A1
公开(公告)日：2023-07-27
申请号：US18156497
申请日：2023-01-19
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , Yibin ZHENG , Jason O'CONNOR , Kerrie GALLAGHER , Lindsay PHILBRICK , Alex NGUYEN , Joshua WILLIAMS
CPC classification number: A61M5/172 , A61B5/14532 , A61M2230/201
Abstract: Exemplary embodiments may provide a user interface and logic for assisting a user in calculating a proper medicament bolus dosage. The user interface may be simple and easy to understand. The user interface may clearly specify needed inputs, such as a carbohydrates amount for a meal that is about to be ingested and the current glucose level reading for the user. Entered inputs may be displayed on the user interface. The user interface may depict key calculated values resulting from calculations that involve the inputs, including the total bolus dosage calculation. The user interface also may depict the values that contribute to the total bolus dosage calculation. Some of the input values, such as carbohydrates amount, may be prepopulated by the management device or medicament delivery device. The user interface may permit overriding of prepopulated input values.
-
公开(公告)号：US20230166034A1
公开(公告)日：2023-06-01
申请号：US17752236
申请日：2022-05-24
Applicant: Insulet Corporation
Inventor： Joon Bok LEE , Yibin ZHENG , Jason O'CONNOR , Ashutosh ZADE
CPC classification number: A61M5/1723 , A61M5/14244 , G16H20/17 , A61M2230/201 , A61M2005/14208
Abstract: Disclosed herein is a method for execution by a drug delivery device for determining an optimal dose of a liquid drug for current cycle of a medication delivery algorithm, the method utilizing a stepwise evaluation of a model and a cost function across a coarse search space consisting of coarse discrete quantities of the drug and a refined search space consisting of refined discrete quantities of the drug.
-
Patent Agency Ranking
公开(公告)号：US20220379028A1
公开(公告)日：2022-12-01
申请号：US17818504
申请日：2022-08-09
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , Yibin ZHENG , Jason O'CONNOR
Abstract: Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.
-
公开(公告)号：US20220293234A1
公开(公告)日：2022-09-15
申请号：US17691829
申请日：2022-03-10
Applicant: Insulet Corporation
Inventor： Joon Bok LEE , Eric BENJAMIN , Jason O'CONNOR , Yibin ZHENG
Abstract: The exemplary embodiments may modify a glucose cost component of the cost function of the control loop of an insulin delivery device to compensate for persistent positive low level glucose excursions relative to a target glucose level. The exemplary embodiments may enable use of different glucose cost component functions for different glucose levels of the user. These glucose cost component functions may be employed in piecewise fashion with a different piece being applied for each respective range of glucose level values for the user. The final glucose cost function for calculating the glucose cost component may be a weighted combination of a piecewise glucose cost function and a weighted standard cost function (such as a quadratic function). The weights may reflect the magnitude and/or persistence of glucose excursions relative to a target glucose level.
-
28.发明申请公开(公告)号：US20220288300A1
公开(公告)日：2022-09-15
申请号：US17330115
申请日：2021-05-25
Applicant: Insulet Corporation
Inventor： Joon Bok LEE , Yibin ZHENG , Jason O'CONNOR , Trang LY
Abstract: The exemplary embodiments provide medicament delivery devices that use cost functions in their control systems to determine medicament dosages. The cost function may have a medicament cost component and a performance cost component. The exemplary embodiments may use cost functions having medicament cost components that scale asymmetrically for different ranges of inputs (i.e., different candidate medicament dosages). The variance in scaling for different input ranges provides added flexibility to tailor the medicament cost component to the user and thus provide better management of medicament delivery to the user and better conformance to a performance target. The exemplary embodiments may use a cost function that has a medicament cost component (such as an insulin cost component) of zero for candidate dosages for a range of candidate dosages (e.g., below a reference dosage).
-
公开(公告)号：US20220287633A1
公开(公告)日：2022-09-15
申请号：US17685937
申请日：2022-03-03
Applicant: Insulet Corporation
Inventor： Yibin ZHENG , Ashutosh ZADE , Joon Bok LEE
Abstract: Disclosed are processes and techniques implementable by devices and a drug delivery system to maintain optimal drug delivery for a user according to a user's diabetes treatment plan. The disclosed techniques enable a drug delivery device that received an analyte measurement value from an analyte sensor during a prior cycle time to determine a present analyte measurement value has not been received during a present cycle time. A processor of the drug delivery device may, in response to the determination, initiate an action to obtain the present analyte measure value from another device or an estimate of the present analyte measurement value. Based on an outcome of the initiated action, the processor may calculate a dosage of the drug using the present analyte measurement value or information related to the present analyte measurement value. The drug delivery device may also be operable to output the calculated dosage of the drug.
-
公开(公告)号：US20220241503A1
公开(公告)日：2022-08-04
申请号：US17578716
申请日：2022-01-19
Applicant: Insulet Corporation
Inventor： Yibin ZHENG , Joon Bok LEE
Abstract: The disclosed examples provide techniques and devices for determining a daily basal profile or an adjusted basal need for a drug based on a collection of data that is filtered and processed. A controller may be configured to evaluate a history of drug delivery in both basal and bolus dosages and generate a daily basal profile or an adjusted basal need that is a time dependent that may be used to schedule basal dosages of a drug that more closely addresses a user's drug needs over the course of a time period, such as a day, week or the like.
-
-
-
-
-
-
-
-
-
Search Results
111
records
(took 0.022 seconds)
